LACTOBACILLI FOR SKIN AGING

Lactobacillus bacteria are used to maintain and stimulate natural cytokine production in keratinocytes, addressing skin aging by enhancing metabolic activity, cell viability, and structural integrity, thus promoting skin rejuvenation and anti-aging.

JP2024543178APending Publication Date: 2024-11-19INT N&H DENMARK APS

Patent Information

Application Number
JP2024531603
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-30
Filing Date
2022-11-25
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

There is a need for effective means to prevent, reduce, or treat skin aging by maintaining metabolic activity and cell viability, promoting natural and endogenous homeostatic cytokine production, and enhancing the structural integrity of the skin barrier.

Method used

The use of bacteria from the genus Lactobacillus, specifically Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, and Lactiplantibacillus plantarum, or mixtures thereof, to maintain and stimulate the natural and endogenous homeostatic cytokine production of keratinocytes, thereby increasing metabolic activity and cell viability, and improving the structural integrity of the skin barrier.

Benefits of technology

These bacteria enhance skin rejuvenation and anti-aging effects by maintaining and stimulating the natural cytokine production of keratinocytes, slowing down the decline in metabolic activity and cell viability, and improving the structural integrity and strength of the skin barrier.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543178000001_ABST
    Figure 2024543178000001_ABST
Patent Text Reader

Abstract

The present invention relates to the use of bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, Lactiplantibacillus plantarum or mixtures thereof for preventing, reducing or treating skin aging in a subject.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a novel use of bacteria of the genus Lactobacillus for skin aging, in particular bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, Lactiplantibacillus plantarum or mixtures thereof. The present invention also relates to a composition, skin care composition, food, dietary supplement, nutraceutical or pharma- ceutically acceptable composition comprising said bacteria. [Background technology]

[0002] Human skin is the largest organ of the human body and a barrier that separates the body from the external environment. One of its most important roles is to protect the body from water loss from the inside to the outside and from microbial infection from the outside. Human skin consists of two main layers of cells, the epidermis and the dermis. The epidermis is the outermost layer of the skin and is formed mainly from terminally differentiated keratinocytes and lipids, with living dividing keratinocytes located below the terminally differentiated keratinocytes. The main function of the epidermis is to form a permeable barrier against environmental challenges, such as UV radiation, heat, chemicals, pollution, and pathogens such as bacteria, fungi, parasites and viruses. It also protects the body from uncontrolled evaporation of water from the inside and maintains hydration balance and skin metabolism. Epidermal tight junctions play an important role in the skin barrier function being flexible and interacting with other components in the skin.

[0003] Skin aging begins at birth, but as we age, we show obvious and visible signs of aging. Skin aging can be caused by intrinsic or extrinsic aging. The term skin exposome refers to these external and internal factors and their interactions that contribute to skin aging. Various external factors, such as solar radiation (ultraviolet, visible and infrared), heat, air pollution, tobacco smoke, alcohol consumption, nutrition, as well as some less clear-cut factors such as stress, lack of sleep, temperature, and the use of some cosmetic products, can contribute to skin aging. These factors affect not only the epidermis but also the dermis of the skin, contributing to skin aging at multiple levels. Various disease states can also contribute to aging. For example, the function of tight junctions is known to be disrupted in skin diseases such as psoriasis and atopic dermatitis, as well as during aging. Skin aging is therefore a complex biological process that is influenced by a combination of intrinsic or endogenous and extrinsic or exogenous factors.

[0004] In the dermis, dermal fibroblasts, the most abundant cell type, are responsible for generating connective tissue by producing the extracellular matrix (ECM). This extracellular matrix (ECM) is composed of two major classes of macromolecules: proteoglycans (PGs) and fibrous proteins, the most abundant of which are type I collagen fibrils, elastin, laminin, and fibronectin. During aging, collagen fibrils are fragmented and fibroblasts produce less ECM proteins and more matrix metalloproteinases (MMPs) that degrade the ECM, resulting in an imbalance of ECM.

[0005] In addition to changes in collagen and MMP, the following changes can be induced in aging: nuclear and mitochondrial DNA mutations, single-strand breaks, and oxidized pyrimidine bases are induced; among others, membrane protein carbonylation and lipid peroxidation are increased, and apoptosis of epidermal keratinocytes is increased. Many cytokines peak in vivo in early life and then decrease. Cytokines expressed in cells that form different layers of the skin affect the expression of cells in adjacent tissue parts. In skin problems, cytokines produced and secreted by keratinocytes in the epidermis affect cells in the dermis, or fibroblasts, and their activity and extracellular matrix production; likewise, fibroblast-derived cytokines stimulate keratinocyte proliferation, resulting in the amplification of the early signaling loop.

[0006] In addition to these changes, skin damage induced by cigarette smoking and air pollutants activates the aryl hydrocarbon receptor (AhR) pathway, a ligand-dependent transcription factor that mediates the toxicity induced by several environmental pollutants, which may be involved in the known premature skin aging effects.

[0007] Furthermore, skin barrier function is important to protect the skin from external pollutants, and therefore proper function of the skin barrier is also important to prevent aging. The skin barrier is a highly organized multicellular layered structure that provides an important defense mechanism. In addition to lipids in the epidermis, tight junctions, hyaluronic acid, natural moisturizing factors and osmolytes in the epidermis have been shown to contribute to overall skin barrier function. In aged human skin, there is a decrease in the expression of tight junction components claudin-1 and occludin, as well as an abnormal increase in claudin-6, which reduces tight junction barrier function. Thus, the epidermal tight junction barrier of the skin is disrupted during aging, and subsequent injury results in reduced recovery of function due to a decrease in homotypic cell-cell adhesion molecules or changes in cytokine production. In particular, IL-1α production is stimulated upon injury, and knockout of the receptor for this cytokine exacerbates barrier dysfunction and reduces recovery. It has also been shown that proper skin barrier function in aged mice protects against age-related systemic inflammation, and cytokines can also affect the barrier. Depending on the cytokine, it can be pro-inflammatory, such as IL-1, IL-6, IL-8, TNF-α, or anti-inflammatory, such as IL-10 or IL-4, which can be secreted by a variety of cell types, including cells in the skin. Transepidermal electrical resistance (TEER) can be used to measure the integrity of epidermal tight junctions and skin barrier strength.

[0008] Since skin health and beauty are considered to be one of the main factors that represent the overall "happiness" and "health" perception in humans, several anti-aging strategies have been developed in the last few years.However, there is a continuous need for products and methods that can prevent, reduce or treat skin aging, not only for therapeutic reasons but also for non-therapeutic use, for example for cosmetic or skin care applications. Summary of the Invention [Problem to be solved by the invention]

[0009] It is an object of the present invention to provide a means for preventing, reducing or treating skin aging in a subject. In particular, it is an object of the present invention to provide a means for maintaining metabolic activity / cell viability in the skin, increasing metabolic activity / cell viability in the skin, or delaying the decrease in metabolic activity and / or cell viability in the skin. Furthermore, it is an object of the present invention to provide a means for skin rejuvenation and anti-aging purposes, to maintain and stimulate the natural and endogenous homeostatic cytokine production of the epidermal skin of keratinocytes, which decreases during aging. It is yet another object of the present invention to provide a means for maintaining and stimulating the natural and endogenous homeostatic cytokine production of the epidermal skin of keratinocytes, to maintain metabolic activity / cell viability in the skin, increasing metabolic activity / cell viability in the skin, or delaying the decrease in metabolic activity and / or cell viability in the skin. It is yet another object of the present invention to provide a means for increasing and improving the structural integrity and strength of the skin barrier by promoting the production of homeostatic cytokines in keratinocytes. It is yet another object of the present invention to provide a means of maintaining and stimulating the natural and endogenous homeostatic cytokine production of keratinocytes in the epidermis skin in order to affect cells or fibroblasts in the dermis and their anti-aging activity and extracellular matrix production for anti-aging purposes. [Means for solving the problem]

[0010] In one aspect, the present invention relates to the non-therapeutic use of bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or mixtures thereof for preventing, reducing or treating skin aging in a subject.

[0011] In another aspect, the present invention relates to a bacterium of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or a mixture thereof for use in preventing, reducing or treating skin aging in a subject.

[0012] In a further aspect, the present invention relates to a non-therapeutic use of a composition comprising one or more bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or a mixture thereof for preventing, reducing or treating skin ageing in a subject.

[0013] In a further aspect, the present invention relates to a composition comprising one or more bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum for use in preventing, reducing or treating skin aging in a subject.

[0014] In another aspect, the present invention relates to a method of preventing, reducing or treating skin aging in a subject in need thereof, comprising administering to the subject a composition comprising an effective amount of one or more bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, or a mixture thereof. [Brief description of the drawings]

[0015] [Figure 1] Graph showing the effect of Ls-33, Lp-12407, Lpc-37, Lp-12418 and HN001 strains on normal human epidermal keratinocyte (NHEK) cell metabolic activity (viability) under hyperosmotic stress (induced by NaCl) compared to NaCl stress control, with medium control values ​​normalized to 100% metabolic activity (viability). Statistical significance is indicated as follows: ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. Ordinary one-way ANOVA, Dunnett's multiple comparison test. [Diagram 2] Graph showing the effect of Ls-33, Lp-12407, Lpc-37, Lp-12418 and HN001 strains on normal human epidermal keratinocyte (NHEK) cell confluency as a percentage compared to medium control. Statistical significance is indicated as follows: *p<0.05. Ordinary one-way ANOVA, Dunnett's multiple comparison test. [Diagram 3]Graph showing the effect of Ls-33, Lp-12407, Lpc-37, Lp-12418 and HN001 strains on normal human epidermal keratinocyte (NHEK) cell confluency under hyperosmotic stress (induced by NaCl) compared to NaCl stress control, expressed as percentage. Statistical significance is indicated as follows: ****p<0.0001, **p<0.01, *p<0.05. Ordinary one-way ANOVA, Dunnett's multiple comparison test. [Figure 4] Graph showing the synthesis of IL-1α in pg / ml of Ls-33, Lp-12407, Lpc-37, Lp-12418 and HN001 strains incubated with normal human epidermal keratinocyte (NHEK) cells under hyperosmotic stress (induced by NaCl) compared to NaCl stress control. Statistical significance is indicated as follows: ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. Ordinary one-way ANOVA, Dunnett's multiple comparison test. [Diagram 5] Graph showing the synthesis of IL-6 in pg / ml of Ls-33, Lp-12407, Lpc-37, Lp-12418 and HN001 strains incubated with normal human epidermal keratinocyte (NHEK) cells compared to cell culture medium control. Statistical significance is indicated as follows: ****p<0.0001, ***p<0.001. Ordinary one-way ANOVA, Dunnett's multiple comparison test. [Figure 6] Graph showing the synthesis of IL-6 in pg / ml of Ls-33, Lp-12407, Lpc-37, Lp-12418 and HN001 strains incubated with normal human epidermal keratinocyte (NHEK) cells under hyperosmotic stress (induced by NaCl) compared to NaCl stress control. Statistical significance is indicated as follows: ****p<0.0001, ***p<0.001, **p<0.01. Ordinary one-way ANOVA, Dunnett's multiple comparison test. [Figure 7]Graph showing the synthesis of IL-8 in pg / ml of Ls-33, Lp-12407, Lpc-37, Lp-12418 and HN001 strains incubated with normal human epidermal keratinocyte (NHEK) cells compared to cell culture medium control. Statistical significance is indicated as follows: ****p<0.0001, **p<0.01, *p<0.05. Ordinary one-way ANOVA, Dunnett's multiple comparison test. [Figure 8] Graph showing the synthesis of IL-8 in pg / ml of Ls-33, Lp-12407, Lpc-37, Lp-12418 and HN001 strains incubated with normal human epidermal keratinocyte (NHEK) cells under hyperosmotic stress (induced by NaCl) compared to NaCl stress control. Statistical significance is indicated as follows: ****p<0.0001, ***p<0.0001, **p<0.001, *p<0.05. Ordinary one-way ANOVA, Dunnett's multiple comparison test. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] advantage Surprisingly, the inventors have found that the use of bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or mixtures thereof is able to maintain metabolic activity / cell viability in the skin, increase metabolic activity / cell viability in the skin or slow down the decrease in metabolic activity and / or cell viability in the skin.

[0017] Furthermore, the inventors have found that bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, or mixtures thereof, can also provide a means for skin rejuvenation and anti-aging to maintain and stimulate the natural and endogenous homeostatic cytokine production of epidermal skin in keratinocytes, which decreases during aging. It has been discovered that bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, or mixtures thereof, can maintain and stimulate the natural and endogenous homeostatic cytokine production of epidermal skin in keratinocytes, maintain metabolic activity / cell viability in the skin, increase metabolic activity / cell viability in the skin, or delay the decrease in metabolic activity and / or cell viability in the skin.

[0018] Furthermore, it has been found that bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, or mixtures thereof, can increase and improve the structural integrity and strength of the skin barrier by promoting the production of homeostatic cytokines in keratinocytes.

[0019] Furthermore, it has been discovered that bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, or mixtures thereof, can maintain and stimulate the natural and endogenous homeostatic cytokine production of keratinocytes, affecting cells in the dermis, or fibroblasts, as well as their anti-aging activity and extracellular matrix production for anti-aging purposes. This demonstrates the ability of bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, or mixtures thereof, to prevent, reduce or treat skin aging in a subject.

[0020] bacteria The bacteria used in the present invention are selected from the genus Lactobacillus.

[0021] Preferably, the Lactobacillus used in the present invention is a Lactobacillus generally recognized as safe, preferably GRAS approved. Generally Recognized as Safe (GRAS) is a designation by the American Food and Drug Administration (FDA) that a chemical or substance added to food is considered safe by experts, and therefore is exempt from normal Federal Food, Drug, and Cosmetic Act (FFDCA) food additive tolerance requirements.

[0022] Preferably, the bacterial strain of the present invention is selected from bacterial strains of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum, or mixtures thereof.

[0023] In one embodiment, the present invention relates to the non-therapeutic use of bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or mixtures thereof for preventing, reducing or treating skin aging in a subject.

[0024] The term "subject" as used herein means an animal having skin that separates and defines the animal from the outside from the inside. Preferably, the subject is a mammal.

[0025] In certain aspects of the invention, the subject may suitably be a human.

[0026] In one embodiment, the subject may be female.

[0027] In one embodiment, the subject may be male.

[0028] In one embodiment, the subject may be of a non-binary gender.

[0029] In one embodiment, the subject is not a child. As used herein, the term "child" refers to a human under the age of 7.

[0030] In one embodiment, the subject is a human aged 8 years or older.

[0031] In one embodiment, the subject is a human aged 16 years or older.

[0032] In one embodiment, the subject is a human aged 18 years or older.

[0033] In one embodiment, the subject is a healthy subject.

[0034] In one embodiment, the subject suffers from cancer, chronic inflammation, skin infection, or any other temporary or chronic medical condition that contributes to skin aging.

[0035] Non-therapeutic uses include, but are not limited to, cosmetic or skin care uses or purposes.Accordingly, the invention described herein also relates to cosmetic or skin care uses of bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, or mixtures thereof, for preventing, reducing, or treating skin aging in a subject.

[0036] According to one embodiment, bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or mixtures thereof maintain metabolic activity / cell viability in the skin, increase metabolic activity / cell viability in the skin or slow the decrease in metabolic activity and / or cell viability in the skin.

[0037] Keratinocytes can detect a wide range of small molecular motifs present on bacteria and other microorganisms, called pathogen-associated molecular patterns (PAMPs), which are present on both gram-positive and gram-negative bacteria. Recognition of PAMPs occurs through pattern recognition receptors, such as toll-like receptors (TLRs). Keratinocytes are therefore part of the first line of defense mechanisms or innate immunity, producing factors important in homeostasis and tissue repair, and triggering immune responses dependent on activated PAMPs and activated receptors. By secreting cytokines and chemokines, keratinocytes can recruit, activate and regulate immune cells. Although not all signals cause inflammation, they exhibit stimulatory effects, preparing and educating the immune system for possible encounters with pathogens, limiting tissue inflammation and microbial translocation. This can be achieved by integrating signals from microbial-derived products into epithelial cells, which integrate these multiple signals to ensure barrier integrity and tissue homeostasis. Inflammation is also important in skin repair processes, such as during wound healing, and it is therefore desirable to target the inflammatory response to improve healing outcomes and skin regeneration.

[0038] The function and expression of structural proteins involved in skin barrier formation are highly regulated in a differentiation-related manner by cytokines and other signaling molecules. Defects in the skin barrier and desquamation of keratinocytes can lead to impaired epidermal barrier and allow environmental toxic pollutants, allergens, and pathogens to enter the skin. Keratinocytes also express various immune markers, cytokines, and effector molecules when activated by injury, such as during wound healing, or together with external pathogens. The hyperosmotic stress encountered by keratinocytes is part of the normal differentiation process, but is also experienced under pathological conditions. This may contribute to the formation of irritant contact dermatitis, a frequent occupational disorder. UV irradiation also causes oxidative stress that disrupts ion regulation in keratinocytes, leading to cell shrinkage and hyperosmotic stress. Hyperosmotic stress has been shown to induce multiple changes in cells and can prime cells for apoptosis and inhibit cell proliferation. When induced with 0.5M NaCl in NHEKs, it has been shown to be proinflammatory and increase expression of cytokines such as IL-1α, IL-1β, IL-6, and IL-8, but not IL-10. In the present invention, stress was induced with 0.15M (150 mM) NaCl to provide a milder stimulus that did not induce cell death.

[0039] Skin aging, like aging in other organs, is characterized by the progressive loss of skin cell functionality and regeneration capacity. Similarities exist between the effects of intrinsic and extrinsic aging. The most obvious changes during skin aging are skin thinning and impaired skin recovery, as well as loss of metabolic turnover or aging and structural changes that occur over time. By promoting proliferation, the production of cytokines stimulated by lactobacilli participates in skin homeostasis by increasing survival and proliferation, thereby enhancing the natural regeneration process capacity of the skin, which decreases during skin aging. By controlling homeostatic immunity, these lactobacilli strains enhance the natural defense mechanisms against pathogens and various environmental factors that enhance skin aging.

[0040] Cytokines are added to some cosmetic products as anti-aging ingredients, and in our invention, probiotics regulate the natural and endogenous cytokine production of keratinocytes for skin rejuvenation and anti-aging purposes. Aging is in many ways related to wound healing in a way that overcomes the genetic repair mechanisms of the skin that are reduced during aging, and the relevant cytokines in wound healing have been shown to be important in skin aging as well. Topical administration or ingestion of lactobacillus strains stimulates the skin's own cytokine production, slowing down or reversing the manifestation of skin aging. Thus, in skin keratinocytes, the described lactobacillus strains can improve the structural integrity and strength of the skin barrier by promoting the production of homeostatic cytokines.

[0041] In another embodiment of the present invention, bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum or mixtures thereof maintain and stimulate natural and endogenous homeostatic cytokine production in epidermal skin of keratinocytes.

[0042] Aging is in many ways linked to wound healing in a way that overcomes the genetic repair mechanisms of the skin that are reduced during aging, and the relevant cytokines in wound healing have been shown to be important in skin aging as well. Thus, bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum or mixtures thereof provide a means for skin rejuvenation and anti-aging purposes to maintain and stimulate the natural and endogenous homeostatic cytokine production of the epidermal skin in keratinocytes that is reduced during aging.

[0043] The maintenance and stimulation of natural and endogenous homeostatic cytokine production of keratinocytes influences cells in the dermis, or fibroblasts, and their anti-aging activity and extracellular matrix production.

[0044] According to the present invention, maintaining and stimulating the natural and endogenous homeostatic cytokine production of epidermal skin keratinocytes maintains metabolic activity / cell viability in the skin, increases metabolic activity / cell viability in the skin, or slows the decline in metabolic activity and / or cell viability in the skin.

[0045] In a further embodiment of the invention, the bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or mixtures thereof increase and improve the structural integrity and strength of the skin barrier, which is achieved by the production of homeostatic cytokines in keratinocytes.

[0046] In particular, the bacterium of the invention is selected from the strains Ls-33, Lpc-37, HN001, Lp-12407 and Lp12418.

[0047] The strains may be used individually or in combination, for example, in skin care compositions, dietary supplements, nutraceuticals, foods, or pharma- ceutically acceptable compositions.

[0048] The bacterial strains of the present invention are all commercially available from DuPont Nutrition Biosciences ApS.

[0049] The bacterial strains were also deposited according to the Budapest Treaty at the Leibniz-Institut Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Inhoffenstrasse 7B, 38124 Braunschweig, Germany, by DuPont Nutrition Biosciences ApS, Langebrogade 1, DK-1411 Copenhagen K, Denmark, where they are recorded under the following accession numbers: 1. Strain Ls-33 (DGCC9868); deposited on February 23, 2021 under registration number DSM33831. 2. Lpc-37 (DGCC4981) strain; deposited on October 5, 2017 under registration number DSM32661. 3. Strain HN001 (DGCC1460); deposited on May 7, 2021 under registration number DSM 22876. 4. Strain Lp12418 (DGCC12418); deposited on September 27, 2017 under the accession number DSM32655. 5. Lp-12407 (DGCC12407) strain; deposited on September 27, 2017 under registration number DSM32654.

[0050] In a particular embodiment according to the invention, the bacterium of the species Ligilactobacillus salivarius is the Ligilactobacillus salivarius strain Ls-33 (Ls-33).

[0051] In another embodiment, the bacterium of the species Lacticaseibacillus paracasei is the Lacticaseibacillus paracasei strain Lpc-37 (Lpc-37).

[0052] In a further embodiment, the bacterium of the species Lacticaseibacillus rhamnosus is the Lacticaseibacillus rhamnosus HN001 (HN001) strain.

[0053] In another embodiment, the bacterium of the species Lactiplantibacillus plantarum is the Lactiplantibacillus plantarum strain Lp-12407 (Lp-12407) and / or the Lactiplantibacillus plantarum strain Lp-12418 (Lp-12418).

[0054] In the dermis, dermal fibroblasts, the most abundant cell type, are responsible for generating connective tissue by producing extracellular matrix (ECM). During aging, collagen fibrils are fragmented, and fibroblasts produce less ECM proteins and more matrix metalloproteinases (MMPs) that degrade ECM, resulting in an imbalance of ECM. In a further embodiment, the prevention, reduction or treatment of skin aging in a subject is achieved by maintaining, increasing or slowing the decrease in metabolic activity / cell viability in the skin and / or increasing or maintaining the natural and endogenous homeostatic cytokine production of keratinocytes, in order to affect cells in the dermis, or fibroblasts, and their anti-aging activity and extracellular matrix production for anti-aging purposes.

[0055] In a further embodiment, the present invention relates to skin aging due to intrinsic and extrinsic factors such as, but not limited to, oxidative damage, DNA damage, impaired DNA repair, impaired cell division, excessive inflammation, inflammation, immune disorders, excessive cell death, sun, sunburn, collagen damage, elastin damage, aging, telomere shortening, impaired expression of antioxidant enzymes, impaired activity of antioxidant enzymes, infrared or UV radiation, heat, hormonal reasons, malnutrition, dehydration, temperature, tobacco smoking, stress, lack of sleep, pollution, or alcohol consumption.

[0056] In one embodiment, the bacteria used in the present invention are probiotic bacteria. The term "probiotic bacteria" is defined herein to cover any non-pathogenic bacteria that, when administered live in sufficient quantities, for example orally or topically, confer a health benefit to the host. Probiotic strains also generally have the ability to survive passing through the upper part of the gastrointestinal tract when intended for oral use. They are non-pathogenic, non-toxic, and exert a beneficial effect on health, on the one hand, through their ecological interaction with the resident microflora, and on the other hand, through their ability to positively affect the immune system via "MALT" (mucosa-associated lymphoid tissue).

[0057] Probiotics can form part of the resident flora during the administration period. This colonization (or transient colonization) allows probiotic bacteria to exert beneficial effects such as, for example, suppression of potentially pathogenic bacteria, resistance to their colonization or competitive exclusion, and normalization of disturbed microflora by interacting with the intestinal immune system or regulating fermentation of the intestinal microflora. Probiotics also mediate health benefits through the production of enzymes or vitamins or other bioactive substances, through regulation of bile acid metabolism, and through neutralization of harmful metabolic products produced by other microorganisms.

[0058] In a preferred embodiment, the bacteria used in the present invention is a probiotic Lactobacillus.

[0059] The bacteria can be used in any form that is capable of exerting the effects described herein. For example, the bacteria can be viable, dormant, inactivated, lysed, or killed bacteria. Preferably, the bacteria is in a live form.

[0060] In a preferred embodiment, the bacteria is in a lysed form.

[0061] The bacterium may comprise the entire bacterium or may comprise bacterial components, including, but not limited to, bacterial cell wall components such as peptidoglycan, lipoteichoic acid, bacterial nucleic acids such as DNA and RNA, bacterial membrane components, and bacterial structural components such as proteins, carbohydrates, lipids, and combinations thereof, such as lipoproteins, glycolipids, and glycoproteins.

[0062] Bacteria may also or alternatively contain bacterial metabolites. As used herein, the term "bacterial metabolites" includes all molecules produced or modified by bacteria as a result of bacterial metabolism during bacterial growth, survival, persistence, migration or existence, during the manufacture and storage of probiotic products, and during gastrointestinal transit in mammals. Examples include, but are not limited to, all organic acids, inorganic acids, bases, proteins and peptides, enzymes and coenzymes, amino acids and nucleic acids, carbohydrates, lipids, glycoproteins, lipoproteins, glycolipids, vitamins, all biologically active compounds, metabolites containing inorganic components, and all small molecules, such as molecules containing nitrite or sulfite.

[0063] In another preferred embodiment, the bacteria is in a postbiotic form.

[0064] Postbiotics refer to products or metabolic by-products or metabolites secreted by live bacteria produced in a matrix by fermentation or released after bacterial lysis, including but not limited to microbial cell fractions, proteins, enzymes, peptides, teichoic acids, peptidoglycan-derived muropeptides, polysaccharides, exopolysaccharides, cell surface proteins, pilus-like structures, lipids and organic acids. These postbiotics exhibit anti-inflammatory, immunomodulatory, anti-obesity-inducing, anti-hypertensive, hypocholesterolemic, anti-proliferative and / or antioxidant properties due to their well-defined chemical structure, safe dosage parameters, long shelf life and content of various signaling molecules.

[0065] The present invention further provides mutants, variants and / or progeny of the bacterial strains Ligilactobacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus rhamnosus HN001 (HN001), Lactiplantibacillus plantarum Lp-12407 (Lp-12407) and Lactiplantibacillus plantarum Lp-12418 (Lp-12418).

[0066] As used herein, the term "mutant" refers to any microorganism resulting from the modification of Ligilactobacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus rhamnosus HN001 (HN001), Lactiplantibacillus plantarum Lp-12407 (Lp-12407) and Lactiplantibacillus plantarum Lp-12418 (Lp-12418) strains. For example, mutants may be microorganisms resulting from genetically modifying these strains.

[0067] As used herein, the term "mutant" refers to naturally occurring microorganisms derived from the strains Ligilactobacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus rhamnosus HN001 (HN001), Lactiplantibacillus plantarum Lp-12407 (Lp-12407) and Lactiplantibacillus plantarum Lp-12418 (Lp-12418). For example, a mutant may be a microorganism resulting from adaptation to a particular environmental or cell culture condition.

[0068] As used herein, the term "progeny" refers to any microorganism resulting from the reproduction or propagation of any one of the following strains: Ligilactobacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus rhamnosus HN001 (HN001), Lactiplantibacillus plantarum Lp-12407 (Lp-12407), and Lactiplantibacillus plantarum Lp-12418 (Lp-12418). Thus, "progeny" refers to any direct descendant of any one of these strains. Thus, the progeny strains themselves can be identified as the same strain as the parent strains (i.e., Ligilactobacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus rhamnosus HN001 (HN001), Lactiplantibacillus plantarum Lp-12407 (Lp-12407) and Lactiplantibacillus plantarum Lp-12418 (Lp-12418) strains). It will be apparent to one of skill in the art that due to the process of asexual reproduction, the progeny strain will be substantially genetically identical to the parent strain. Thus, in one embodiment, the progeny may be genetically identical to the parent strain and may be considered to be a "clone" of the parent strain. Alternatively, the progeny may be substantially genetically identical to the parent strain.

[0069] The mutants, variants or progeny may have at least 90, 95, 98, 99, 99.5 or 99.9% sequence identity with their parent strain over the entire length of the bacterial genome. Furthermore, the mutants, variants or progeny may retain the same phenotype as the deposited parent strain, for example, the mutants, variants or progeny may exhibit the same or comparable effects on in vitro cell viability, cell confluency, and maintenance or stimulation of natural and homeostatic cytokine production.

[0070] For the purposes of the present invention, any mutants, variants and / or progeny of the bacterial strains Ligilactobacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus rhamnosus HN001 (HN001), Lactiplantibacillus plantarum Lp-12407 (Lp-12407) and Lactiplantibacillus plantarum Lp-12418 (Lp-12418) are referred to as Ligilactobacillus salivarius. salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus rhamnosus HN001 (HN001), Lactiplantibacillus plantarum Lp-12407 (Lp-12407) and Lactiplantibacillus plantarum Lp-12418 (Lp-12418) strains, respectively.

[0071] Dosage Lactobacillus to be used according to the invention, such as Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum species, such as Ligilactobacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum species, such as Ligilactobacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus Lactiplantibacillus rhamnosus HN001 (HN001), Lactiplantibacillus plantarum Lp-12407 (Lp-12407) and Lactiplantibacillus plantarum Lp-12418 (Lp-12418) strains were cultured at 10 6 ~10 12 CFU of bacteria / g of support, more particularly 10 8 ~10 12 CFU of bacteria / g of support, preferably 10 9 ~10 12 It may be present in CFU of bacteria / g of substrate.

[0072] Suitably, the Lactobacillus genus, such as Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum species, such as Ligilactobacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum species, such as Ligilactobacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus Lactiplantibacillus rhamnosus HN001 (HN001), Lactiplantibacillus plantarum Lp-12407 (Lp-12407), and Lactiplantibacillus plantarum Lp-12418 (Lp-12418) strains were approximately 10 6 ~about 10 12 CFU of microorganisms / dose, preferably about 10 8 ~about 10 12 The microorganism can be administered in CFU of microorganism / dose. The term "per dose" means that this amount of microorganism is provided to the subject either per day or per intake, preferably per day. For example, if the microorganism is administered in a food product, such as yogurt, the yogurt preferably contains about 10 8 ~10 12 Alternatively, however, this amount of microorganisms may be divided into multiple doses, each consisting of a smaller load of microorganisms - so that the total amount of microorganisms received by a subject at any given time, e.g., every 24 hours, is about 10 6 ~about 10 12 CFU of microorganisms, preferably about 10 8 ~about 10 12 As long as it is a CFU of microorganisms.

[0073] According to the present invention, the effective amount of at least one strain of a microorganism is at least 10 6 CFU of microorganisms / dose, preferably about 10 6 ~about 10 12 CFU of microorganisms / dose, preferably about 10 8 ~about 10 12 CFU of microorganism / dose.

[0074] In one embodiment, preferably the genus Lactobacillus, such as Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, such as Ligilactobacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, such as Ligilactobacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus Lactiplantibacillus rhamnosus HN001 (HN001), Lactiplantibacillus plantarum Lp-12407 (Lp-12407) and Lactiplantibacillus plantarum Lp-12418 (Lp-12418) strains were added to the culture medium at approximately 10 6 ~about 10 12 CFU of microorganisms / day, preferably about 10 8 ~about 10 12 CFU of microorganisms / day. Thus, an effective amount in this embodiment is about 10 6 ~about 10 12 CFU of microorganisms / day, preferably about 10 8 ~about 10 12CFU of microorganisms / day.

[0075] CFU stands for “colony forming unit.” By “substrate” is meant a composition, a skin care composition, a dietary supplement, a nutraceutical, a food, or a pharma- ceutically acceptable composition.

[0076] In one embodiment, the present invention provides a bacterium of the genus Lactobacillus, such as Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum species, such as Ligilactobacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, as at least one component of a composition, a skin care composition, a dietary supplement, a nutraceutical, a food, or a pharma- ceutically acceptable composition. paracasei Lpc-37 (Lpc-37), Lacticaseibacillus rhamnosus HN001 (HN001), Lactiplantibacillus plantarum Lp-12407 (Lp-12407) and Lactiplantibacillus plantarum Lp-12418 (Lp-12418) strains.

[0077] composition Although it is possible to administer the Lactobacilli alone (i.e. without any support, diluent or excipient) according to the invention, the Lactobacilli are typically and preferably administered on or in a support as part of a product, in particular as an ingredient or one of the ingredients of a composition, skin care composition, dietary supplement, nutraceutical, food or pharma- ceutically acceptable composition. These products typically contain additional ingredients well known to those skilled in the art.

[0078] In one embodiment, the present invention relates to a composition for oral or topical administration, a skin care composition or a pharma- ceutically acceptable composition. A composition for topical application is a composition that is applied to a specific location on or within the body. In most cases, topical application or administration refers to application to a body surface, such as the skin or mucous membrane, to treat a specific disease, and for example to prevent, reduce or treat skin aging. Topical application can be achieved using a wide range of products as a support, such as, but not limited to, lotions, serums, jellies, creams, gels, emulsions, masks, patches, micellar waters, sticks or ointments.

[0079] In another embodiment, the present invention relates to a composition, skin care composition, dietary supplement, nutraceutical, food or pharma- ceutically acceptable composition comprising bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or mixtures thereof for oral administration.

[0080] A dietary supplement is any product that, when taken orally in pill, capsule, tablet, or liquid form, is intended to supplement a subject's diet.

[0081] Skin Care Composition The present invention also relates to a method for treating or preventing the development of a skin condition comprising administering to a subject a bacteria of the genus Lactobacillus, such as Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, such as Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, in the form of a skin care composition or product, including, but not limited to, an aqueous solution, an emulsion, a serum, a jelly, a mask, a patch, a face mask, a peel-off mask, a lotion, a topical moisturizer, a cream, a paste, a balm, an ointment, a pomade, a gel, a liquid, a spray, a foam, and a kit. The present invention relates to Lacticaseibacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus rhamnosus HN001 (HN001), Lactiplantibacillus plantarum Lp-12407 (Lp-12407) and Lactiplantibacillus plantarum Lp-12418 (Lp-12418) strains.

[0082] The skin care products may also be in the form of make-up, lipstick, mascara, foundation, blush, eyeliner, lip gloss, macroemulsion, sunscreen, sunblock, bath gel, shower gel, body wash, face wash, skin conditioner, cold cream, moisturizer, body spray, soap and body scrub.

[0083] The skin care composition or product may comprise a liquid lotion (true solution) containing water as a solvent and water soluble additives (solutes) such as, but not limited to, actives, fragrances, colorants, preservatives, pH adjusters, chelating agents, or any one or combination thereof.

[0084] The skin care product may also include dispersions, such as, but not limited to, emulsions, such as liquid-in-liquid (water-in-oil, W / O, O / W, W / O / W), suspensions (solid / liquid or liquid / solid), aerosols (liquid / gas or solid / gas), foams / mousses (gas / liquid or gas / emulsion, or gas / solid). Examples of oil-in-water (O / W) emulsions include, but are not limited to, a combination of an aqueous phase, an emulsifier, a fatty phase, and at least one additive. The aqueous phase may include water, a humectant, and a stabilizing agent, such as, but not limited to, a synthetic polymer, a carbomer, a natural polymer, xanthan gum, acacia gum, carrageenan, gellan, or any one combination thereof. The emulsifiers include, but are not limited to, anionic emulsifiers, cationic emulsifiers, nonionic emulsifiers, amphoteric emulsifiers, silicone emulsifiers, and self-emulsifying agents. Fatty phases (lipophilic components) include, but are not limited to, waxes, butters, fatty esters, triglycerides, vegetable oils, mineral oils (paraffins), silicones, and thickeners / oil gelling agents.Additives include, but are not limited to, preservatives, fragrances (most often lipophilic), colorants, antioxidants, chelating agents, actives, pH adjusters (citric acid, lactic acid, AHA), neutralizers / strong base agents such as NaOH, trimethylamine (to gel acrylic polymers), and powders.

[0085] The skin care products include aqueous gels that include an aqueous phase (including water, humectants, actives), a gelling agent (including but not limited to synthetic polymers, natural polymers, xanthan gum, acacia gum, carrageenan, gellan, etc.) and additives (including but not limited to fragrances, high HLB surfactants, colorants, actives, preservative systems, pH adjusters, neutralizing agents, powders, etc.).

[0086] Skin care products include a cleansing / surfactant system (such as but not limited to shampoos, shower gels, micellar waters, etc.) that includes an aqueous phase (water, humectants), surfactants, additives (such as but not limited to fragrances, high HLB surfactants, colorants, actives, preservative systems, pH adjusters, neutralizers, powders, etc.), and optionally a gelling agent (such as but not limited to synthetic polymers, natural polymers, xanthan gum, acacia gum, carrageenan, gellan, etc.).

[0087] In one embodiment, the skin care product or formulation comprising an effective amount of the skin care composition further comprises bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum.

[0088] In another embodiment, the skin product or formulation comprising an effective amount of the skin care composition comprises a bacterium of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, such as Ligilactobacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, such as Ligilactobacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus Lactiplantibacillus plantarum Lp-12407 (Lp-12407) and Lactiplantibacillus plantarum Lp-12418 (Lp-12418) strains and any mixtures thereof.

[0089] Skin products or formulations containing bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum provide skin care benefits by preventing, reducing, or treating skin aging by maintaining, increasing metabolic activity / cell viability in the skin, or slowing the decrease in metabolic activity and / or cell viability in the skin; provide a means for skin rejuvenation and anti-aging to maintain and stimulate the natural and endogenous homeostatic cytokine production of the epidermal skin of keratinocytes, which is decreased during aging; and maintain the natural and endogenous homeostatic cytokine production of the epidermal skin of keratinocytes, which is decreased during aging. and stimulate to maintain metabolic activity / cell viability in the skin, increase metabolic activity / cell viability in the skin, or slow the decline in metabolic activity and / or cell viability in the skin; increase and improve the structural integrity and strength of the skin barrier by promoting homeostatic cytokine production of keratinocytes; maintain and stimulate the natural and endogenous homeostatic cytokine production of epidermal skin of keratinocytes to affect cells in the dermis, or fibroblasts, and their anti-aging activity and extracellular matrix production for anti-aging purposes.

[0090] Bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum used according to the invention, such as Ligilactobacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus rhamnosus, Lactiplantibacillus plantarum, Lactiplantibacillus rhamnosus HN001 (HN001), Lactiplantibacillus plantarum Lp-12407 (Lp-12407) and Lactiplantibacillus plantarum Lp-12418 (Lp-12418) strains or mixtures thereof can be present in the range of 0.1% to 10% by weight based on the total weight of the skin care product. In one aspect, a preferred effective amount of the skin care composition described herein can be at least about 0.1% to 5% by weight based on the total weight of the skin care product. In one aspect, an effective amount of the skin care composition described herein can be at least about 0.1% to 10% by weight based on the total weight of the skin care product. The dermatologically acceptable ingredient can be a dermatologically acceptable carrier that comprises about 10% to about 99% by weight based on the total weight of the skin care product. In one aspect, at least about 0.1%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% to 10% by weight of the total weight of the skin care product is a live bacteria, non-viable bacteria, bacterial lysate or postbiotic as described herein.The effective amount of the skin care composition in the skin care product can be at least about 0.1%-5%, at least about 0.1%-6%, at least about 0.1%-7%, at least about 0.1%-8%, at least about 0.1%-9%, at least about 0.1%-10% by weight based on the total weight of the formulation or skin care product. In one embodiment, the effective amount of the skin care composition in the skin care product can be at least about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3 ... %,1.7%,1.8%,1.9%,2.0%,2.1%,2.2%,2.3%,2.4%,2.5%,2.6%,2.7%,2.8%,2.9%,3.0%,3.1%,3.2%,3.3%,3.4%,3.5%,3.6%,3.7%,3.8%,3.9%,4.0%,4.1%,4.2%,4.3%,4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7. It could be 3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, ~10%.

[0091] The skin care products described herein may further comprise one or more dermatologically or cosmetically acceptable ingredients known or otherwise effective for skin care use, provided that such optional ingredients are physically and chemically compatible with the essential ingredients described herein or do not otherwise unduly impair the stability, aesthetics, or performance of the product. Non-limiting examples of such optional ingredients are disclosed in the International Cosmetic Ingredient Dictionary, Ninth Edition, 2002, and the CTFA Cosmetic Ingredient Handbook, Tenth Edition, 2004.

[0092] In one embodiment, the dermatologically or cosmetically acceptable ingredient is a dermatologically acceptable carrier comprising from about 10% to about 99.9%, alternatively from about 50% to about 95%, alternatively from about 75% to about 95% by weight of a dermatologically acceptable carrier. Carriers suitable for use with the composition can include, for example, those used in the formulation of mousses, tonics, gels, skin moisturizers, and lotions. Carriers include water; organic oils; silicones, such as volatile silicones, amino or non-amino silicone gums or oils, and mixtures thereof; mineral oils; vegetable oils, such as olive oil, castor oil, rapeseed oil, coconut oil, wheat germ oil, sweet almond oil, avocado oil, macadamia oil, apricot oil, safflower oil, candlenut oil, flaxseed oil, tamanu oil, lemon oil, and mixtures thereof; waxes; and organic compounds, such as C2-C10 alkanes, acetone, methyl ethyl ketone, volatile organic C1-C12 alcohols, esters of C1-C20 acids and C1-C8 alcohols. esters such as methyl acetate, butyl acetate, ethyl acetate, and isopropyl myristate, dimethoxyethane, diethoxyethane, C10-C30 fatty alcohols such as lauryl alcohol, cetyl alcohol, stearyl alcohol, and behenyl alcohol; C10-C30 fatty acids such as lauric acid and stearic acid; C10-C30 fatty amides such as lauric acid diethanolamide; C10-C30 fatty alkyl esters such as C10-C30 fatty alkyl benzoates; hydroxypropyl cellulose, and mixtures thereof. In one embodiment, the carrier comprises water, fatty alcohols, volatile organic alcohols, and mixtures thereof. Other carriers can be formulated by one of skill in the art.

[0093] The skin care products described herein may further comprise from about 0.1% to about 10%, alternatively from about 0.2% to about 5.0%, of a gelling agent to help provide a desired viscosity to the composition. Non-limiting examples of optional suitable gelling agents include crosslinked carboxylic acid polymers; unneutralized crosslinked carboxylic acid polymers; unneutralized modified crosslinked carboxylic acid polymers; crosslinked ethylene / maleic anhydride copolymers; unneutralized crosslinked ethylene / maleic anhydride copolymers (e.g., EMA 81 available from Monsanto); unneutralized crosslinked alkyl ether / acrylate copolymers (e.g., SALCARE™ SC90 available from Allied Colloids); unneutralized crosslinked copolymers of sodium polyacrylate, mineral oil, and PEG 1 trideceth-6 (e.g., SALCARE™ SC91 available from Allied Colloids); unneutralized crosslinked copolymers of methyl vinyl ether and maleic anhydride (e.g., STABILEZE™ QM-PVM / MA copolymer available from International Specialty Products); hydrophobically modified ethoxylated urethane polymers (e.g., UCARE™ Polyphobe, an alkali swellable polymer available from Union Carbide). In this context, the term "unneutralized" means that the optional polymer and copolymer gelling agent materials comprise unneutralized acidic monomers.

[0094] The cosmetically acceptable medium may contain fatty substances, generally in a proportion of about 10 to about 90% by weight based on the total weight of the product, and the fatty phase contains at least one liquid, solid or semi-solid fatty substance. Fatty substances include, but are not limited to, oils, waxes, gums, and so-called pasty fatty substances. Alternatively, the product may be in the form of a stable dispersion, such as a water-in-oil or oil-in-water emulsion. In addition, the skin care product may contain one or more conventional cosmetic or dermatological additives or adjuvants, including, but not limited to, antioxidants, preservatives, fillers, surfactants, UVA and / or UVB sunscreens, fragrances, thickeners, humectants, and anionic, nonionic or amphoteric polymers, as well as dyes or pigments (colorants).

[0095] The dermatologically acceptable carrier may be a moisturizer formulation comprising at least one emulsifier, at least one surfactant, or any combination thereof.

[0096] The skin care products may further comprise skin care active ingredient materials including sunscreens, moisturizers, humectants, skin benefit agents, adhesives, such as surfactants, occlusive agents, moisture barriers, lubricants, emollients, anti-aging agents, antistatic agents, abrasives, antimicrobial agents, conditioners, exfoliants, fragrances, thickeners, salts, lipids, phospholipids, vitamins, foam stabilizers, pH adjusters, preservatives, suspending agents, silicone oils, silicone derivatives, essential oils, oils, fats, fatty acids, fatty acid esters, fatty alcohols, waxes, polyols, hydrocarbons, and mixtures thereof.

[0097] Other ingredients that may be included in skin care products include, but are not limited to, at least one active ingredient for treating or preventing a skin condition, for providing a cosmetic benefit, or for providing a moisturizing benefit to the skin, such as zinc oxide, petrolatum, white petrolatum, mineral oil, cod liver oil, lanolin, dimethicone, hard lipids, vitamin A, allantoin, calamine, kaolin, glycerin, or colloidal oatmeal, and combinations thereof, one or more natural moisturizing factors (e.g., ceramides, hyaluronic acid, glycerin, squalane, amino acids, cholesterol, fatty acids, etc.), and / or ... , triglycerides, phospholipids, sphingoglycolipids, urea, linoleic acid, glycosaminoglycans, mucopolysaccharides, sodium lactate, or sodium pyrrolidone carboxylate), glycerides, apricot kernel oil, canola oil, squalane, squalene, coconut oil, corn oil, jojoba oil, jojoba wax, lecithin, olive oil, safflower oil, sesame oil, shea butter, soybean oil, sweet almond oil, sunflower oil, tea oil, shea butter, palm oil, cholesterol, cholesterol esters, wax esters, fatty acids, and orange oil.

[0098] food In one embodiment, Lactobacilli is used according to the present invention in food, such as food supplement, beverage or milk-based powder.Here, the term "food" is used in a broad sense and includes food for humans and food for animals (i.e. feed).In a preferred embodiment, food is for human consumption.

[0099] The food may be in the form of a solution or as a solid, depending on the use and / or the mode of application and / or the mode of administration.

[0100] When used as or in the preparation of a food, such as a functional food, the bacteria of the present invention may be used in combination with one or more of a nutritionally acceptable carrier, a nutritionally acceptable diluent, a nutritionally acceptable excipient, a nutritionally acceptable supplement, or a nutritionally active ingredient.

[0101] By way of example, the bacteria of the present invention can be used as an ingredient for soft drinks, fruit juices or beverages containing whey protein, health teas, cocoa drinks, dairy drinks and lactobacillus drinks, yoghurt and drinking yoghurt, cheese, ice cream, water ice and desserts, confectionery, biscuit cakes and cake mixes, snack foods, balanced foods and beverages, fruit fillings, care glazes, chocolate bakery fillings, cheesecake flavoured fillings, fruit flavoured cake fillings, cake and donut icings, instant bakery filling creams, fillings for cookies, ready to use bakery fillings, low calorie fillings, adult nutritional beverages, vegetable milks, acidified soy / juice beverages, aseptic / retort chocolate beverages, bar mixes, beverage powders, calcium fortified soy / plain and chocolate milk, calcium fortified coffee beverages.

[0102] Advantageously, when the product is a food product, the Lactobacilli should be effective until the usual "best before" or "expiration" date that the food product is offered for sale by the retailer. Preferably, the effective time should extend beyond such date until the end of the normal freshness period when food spoilage becomes evident. The desired length of time and normal shelf life will vary from food product to food product, and those skilled in the art will recognize that shelf life time will vary depending on the type of food product, the size of the food product, storage temperature, processing conditions, packaging materials and packaging equipment.

[0103] Medical Foods In one embodiment, the bacteria of the present invention are in the form of a medical food.

[0104] Preferably, the species of Lactobacillus, such as Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, such as Ligilactobacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, such as Ligilactobacillus salivarius Ls-33 (Ls-33), Lacticaseibacillus paracasei Lpc-37 (Lpc-37), Lacticaseibacillus Lactiplantibacillus rhamnosus HN001 (HN001), Lactiplantibacillus plantarum Lp-12407 (Lp-12407) and Lactiplantibacillus plantarum Lp-12418 (Lp-12418) strains are in the form of medical foods.

[0105] "Medical food" means a food formulated to be consumed or administered with or without medical supervision and intended to treat a specific skin condition or other medical condition for which unique nutritional requirements have been established based on recognized scientific principles.

[0106] Pharmaceutical Compositions The bacteria of the present invention can be used as or in the preparation of a pharmaceutical composition, where the term "pharmaceutical" is used in a broad sense to include human medicine and animal medicine (i.e. veterinary use).

[0107] In a preferred embodiment, the pharma- ceutically acceptable composition is a medicament.

[0108] The pharmaceutical composition may be for therapeutic purposes, which may be curative or palliative or prophylactic in nature. The pharmaceutical composition may be for diagnostic purposes.

[0109] In a preferred embodiment of the invention, the medicament is for topical application.

[0110] In another preferred embodiment of the invention, the medicament is for oral administration.

[0111] The pharma- ceutically acceptable composition or support may be, for example, a formulation or support in the form of a compressed tablet, tablet, capsule, ointment, suppository or drinkable solution cream, foam, gel, lotion, and ointment. Other suitable forms are provided below.

[0112] When used as a pharmaceutical or in the preparation of a pharmaceutical, the compositions of the present invention may be used in combination with one or more of a pharma- ceutical acceptable carrier, a pharma- ceutical acceptable diluent, a pharma- ceutical acceptable excipient, a pharma- ceutical adjuvant, a pharma- ceutical active ingredient.

[0113] The medicament may be in the form of a solution or as a solid, depending on the use and / or the mode of application and / or the mode of administration.

[0114] The lactobacillus of the present invention can be used as a pharmaceutical ingredient, where the composition may be the only active ingredient or at least one of several (i.e. two or more) active ingredients.

[0115] The pharmaceutical ingredient may be in the form of a solution or as a solid, depending on the use and / or the mode of application and / or the mode of administration.

[0116] Lactobacillus bacteria may be used in accordance with the present invention in any suitable form, whether alone or in combination with other components or ingredients. Similarly, combinations comprising the bacteria of the present invention and other components and / or ingredients (i.e., ingredients such as food ingredients, functional food ingredients or pharmaceutical ingredients) may be used in any suitable form.

[0117] Lactobacillus may be used in the form of solid or liquid preparations or alternatives thereof according to the present invention. Examples of solid preparations include, but are not limited to, tablets, capsules, dusts, granules and powders that can be wettable, spray-dried or freeze-dried. Examples of liquid preparations include, but are not limited to, aqueous, organic or aqueous-organic solutions, suspensions and emulsions.

[0118] Suitable examples of forms include one or more of a tablet, pill, capsule, ovule, solution or suspension, which may contain flavorings or colorants, for immediate, delayed, modified, sustained, pulsed or controlled release applications.

[0119] By way of example, when the bacteria of the present invention are used in tablet form for use as a functional ingredient, the tablet may also contain one or more of the following: excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine; disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycolate, croscarmellose sodium and certain complex silicates; granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia; and lubricants such as magnesium stearate, stearic acid, glyceryl behenate and talc. Examples of nutritionally acceptable carriers for use in preparing the forms include, for example, water, salt solutions, alcohol, silicones, waxes, petrolatum, vegetable oils, polyethylene glycol, propylene glycol, liposomes, sugars, gelatin, lactose, amylose, magnesium stearate, talc, surfactants, silicic acid, viscous paraffin, flavor oils, fatty acid mono- and diglycerides, petroethrai fatty acid esters, hydroxymethylcellulose, polyvinylpyrrolidone, and the like.

[0120] Preferred excipients for this form include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols.

[0121] For aqueous suspensions and / or elixirs, the bacteria of the present invention may be combined with various sweetening or flavoring agents, coloring substances or dyes, emulsifying and / or suspending agents, and diluents such as water, propylene glycol, and glycerin, and combinations thereof.

[0122] Forms may also include gelatin capsules; fiber capsules, fiber tablets, and the like; or even fiber drinks.

[0123] Further examples of forms include creams. In some embodiments, the microorganisms used in the present invention may be used in pharmaceutical and / or cosmetic creams, such as, for example, sun creams and / or after-sun creams.

[0124] In one aspect, the bacteria according to the invention may be administered in an aerosol, for example by nasal spray, for example for administration to the respiratory tract.

[0125] Prebiotics In one embodiment, the use of the bacteria of the present invention may further comprise the use of one or more fibers / fibres and / or prebiotics.

[0126] Prebiotics are defined as substrates that are selectively utilized by host microorganisms to confer a health benefit. They are generally ingredients that beneficially affect the health of the host by selectively stimulating the growth and / or activity of one or a limited number of bacteria (particularly, but not limited to, Lactobacillus and / or Lactobacillus), thereby improving the health of the host. Prebiotics can be applied via the oral route, but also topically on other microbiologically colonized sites, for example, on the skin. Typically, prebiotics are carbohydrates (such as oligosaccharides), but this definition does not exclude non-carbohydrates such as polyphenols, or polyunsaturated fatty acids, or other ingredients that can be selectively utilized by a limited number of bacteria to confer a health benefit. The most common forms of prebiotics are nutritionally classified as soluble fiber / (fibre). To some extent, many forms of dietary fiber show some level of prebiotic effect.

[0127] In one embodiment, prebiotics are selectively fermented ingredients that enable specific changes in both composition and / or activity in the gastrointestinal or skin microflora that benefit the well-being and health of the host.

[0128] Suitably, prebiotics may be used in accordance with the present invention in an amount of 0.01-100 g / day, preferably 0.1-50 g / day, more preferably 0.5-20 g / day. In one embodiment, prebiotics may be used in accordance with the present invention in an amount of 1-10 g / day, preferably 2-9 g / day, more preferably 3-8 g / day. In another embodiment, prebiotics may be used in accordance with the present invention in an amount of 5-50 g / day, preferably 10-25 g / day.

[0129] Examples of dietary sources of prebiotics include soy, inulin sources (eg, Jerusalem artichoke, jicama, and chicory root), raw oats, unrefined wheat, unrefined barley, and yacon.

[0130] Examples of suitable prebiotics include alginates, xanthan, pectin, locust bean gum (LBG), inulin, guar gum, galactooligosaccharides (GOS), fructooligosaccharides (FOS), polydextrose (i.e., Litesse®), lactitol, L-arabinose, D-xylose, L-rhamnose, L-mannose, L-fucose, inositol, sorbitol, mannitol, xylitol, fructose, carrageenan, alginates, microcrystalline cellulose (MCC). , betaine, lactosucrose, soy oligosaccharides, isomaltulose (Palatinose™), isomaltooligosaccharides, glucooligosaccharides, xylooligosaccharides, mannooligosaccharides, beta-glucan, cellobiose, raffinose, gentiobiose, melibiose, xylobiose, cyciodextrin, isomaltose, trehalose, stachyose, panose, pullulan, verbascose, galactomannan, (human) milk oligosaccharides and all forms of resistant starch.

[0131] The combination of Lactobacillus according to the present invention with one or more fibers and / or prebiotics may exhibit synergistic effects in certain applications (i.e., an effect that is greater than the additive effect of the bacteria when used separately).

[0132] In one embodiment, bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum or mixtures thereof are used in combination with one or more fibers and / or prebiotics.

[0133] In a particularly preferred embodiment, the Lactobacillus or mixture thereof used in combination with one or more fibers and / or prebiotics is Ligilactobacillus salivarius Ls-33 (Ls-33).

[0134] In a particularly preferred embodiment, the Lactobacillus or mixture thereof used in combination with one or more fibers and / or prebiotics is Lacticaseibacillus paracasei Lpc-37 (Lpc-37).

[0135] In a particularly preferred embodiment, the Lactobacillus or mixtures thereof used in combination with one or more fibers and / or prebiotics is Lacticaseibacillus rhamnosus HN001 (HN001).

[0136] In a particularly preferred embodiment, the Lactobacillus or mixtures thereof used in combination with one or more fibers and / or prebiotics is Lactiplantibacillus plantarum Lp-12407 (Lp-12407).

[0137] In a particularly preferred embodiment, the Lactobacillus or mixture thereof used in combination with one or more fibers and / or prebiotics is Lactiplantibacillus plantarum Lp-12418 (Lp-12418).

[0138] Suitably the prebiotic used is polydextrose, lactitol, inositol, L-arabinose, D-xylose, L-rhamnose, D-mannose, L-fucose, sorbitol, mannitol, xylitol, fructose, carrageenan, alginate, microcrystalline cellulose (MCC), milk oligosaccharides or betaine.

[0139] In a further aspect, the present invention relates to a composition, a skin care composition, a dietary supplement, a nutraceutical, a food, or a pharma- ceutically acceptable composition comprising bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, or a mixture thereof, and one or more fibers and / or prebiotics.

[0140] In one aspect, the prebiotic may be a metabolic product produced by bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, or mixtures thereof, which metabolic product may be utilized as cross-nutrition for other microorganisms when applied topically, for example, on the skin, to beneficially affect health.

[0141] In one embodiment, the prebiotic can be a metabolic product produced by bacteria of the Ligilactobacillus salivarius Ls-33 (Ls-33) strain.

[0142] In one embodiment, the prebiotic can be a metabolic product produced by bacteria of the Lacticaseibacillus paracasei Lpc-37 (Lpc-37) strain.

[0143] In one embodiment, the prebiotic can be a metabolic product produced by bacteria of the Lacticaseibacillus rhamnosus HN001 (HN001) strain.

[0144] In one embodiment, the prebiotic can be a metabolic product produced by bacteria of the Lactiplantibacillus plantarum strain Lp-12407 (Lp-12407).

[0145] In one embodiment, the prebiotic can be a metabolic product produced by bacteria of the Lactiplantibacillus plantarum Lp-12418 (Lp-12418) strain.

[0146] EMBODIMENTS OF THE PRESENTINVENTION For the avoidance of doubt, some of the embodiments to which the present invention pertains are set forth below:

[0147] Embodiment 1: Non-therapeutic use of bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, or mixtures thereof, for preventing, reducing or treating skin aging in a subject.

[0148] Embodiment 2. A non-therapeutic use according to embodiment 1, wherein bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or mixtures thereof maintain metabolic activity / cell viability in the skin, increase metabolic activity / cell viability in the skin or slow the decrease in metabolic activity and / or cell viability in the skin.

[0149] Embodiment 3. Non-therapeutic use according to embodiment 1, wherein bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or mixtures thereof maintain and stimulate the natural and endogenous homeostatic cytokine production of epidermal skin in keratinocytes.

[0150] Embodiment 4. Non-therapeutic use according to embodiment 3, wherein maintaining and stimulating the natural and endogenous homeostatic cytokine production of the epidermal skin of keratinocytes maintains metabolic activity / cell viability in the skin, increases metabolic activity / cell viability in the skin, or slows the decline in metabolic activity and / or cell viability in the skin.

[0151] Embodiment 5. Non-therapeutic use according to embodiment 1, wherein the bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or mixtures thereof increase and improve the structural integrity and strength of the skin barrier.

[0152] Embodiment 6. Non-therapeutic use according to embodiment 5, wherein the increase and improvement of the structural integrity and strength of the skin barrier is achieved by the production of homeostatic cytokines in keratinocytes.

[0153] Embodiment 7. Non-therapeutic use according to embodiment 3, in which the maintenance and stimulation of the natural and endogenous homeostatic cytokine production of keratinocytes has an effect on cells in the dermis, or fibroblasts, and their anti-aging activity and extracellular matrix production.

[0154] Embodiment 8. Non-therapeutic use according to any one of embodiments 1 to 7, wherein the bacterium of the species Ligilactobacillus salivarius is the Ligilactobacillus salivarius strain Ls-33 (Ls-33).

[0155] Embodiment 9. Non-therapeutic use according to any one of embodiments 1 to 7, wherein the bacterium of the species Lacticaseibacillus paracasei is the Lacticaseibacillus paracasei Lpc-37 (Lpc-37) strain.

[0156] Embodiment 10. Non-therapeutic use according to any one of embodiments 1 to 7, wherein the bacterium of the species Lacticaseibacillus rhamnosus is the Lacticaseibacillus rhamnosus HN001 (HN001) strain.

[0157] Embodiment 11. Non-therapeutic use according to any one of embodiments 1 to 7, wherein the bacterium of the species Lactiplantibacillus plantarum is the Lactiplantibacillus plantarum strain Lp-12407 (Lp-12407) and / or the Lactiplantibacillus plantarum strain Lp-12418 (Lp-12418).

[0158] Embodiment 12. Non-therapeutic use according to any one of embodiments 1 to 11, wherein the bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum or a mixture thereof is in live form.

[0159] Embodiment 13. Non-therapeutic use according to any one of embodiments 1 to 11, wherein the bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum or a mixture thereof is in a dissolved form.

[0160] Embodiment 14. Non-therapeutic use according to any one of embodiments 1 to 11, wherein the bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum or a mixture thereof is in a postbiotic form.

[0161] Embodiment 15. A non-therapeutic use according to any one of embodiments 1 to 14, wherein the bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum or a mixture thereof is an ingredient of at least one of a composition, a skin care composition, a dietary supplement, a nutraceutical, a food, or a pharma- ceutically acceptable composition.

[0162] Embodiment 16. Non-therapeutic use according to embodiment 15, wherein the composition, skin care composition or pharma- ceutically acceptable composition is for topical application.

[0163] Embodiment 17. Non-therapeutic use according to embodiment 15, wherein the composition, skin care composition, dietary supplement, nutraceutical, food or pharma- ceutically acceptable composition is for oral administration.

[0164] Embodiment 18. A bacterium of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or a mixture thereof for use in preventing, reducing or treating skin aging in a subject.

[0165] Embodiment 19. A bacterium for use according to embodiment 18, wherein the bacterium or a mixture thereof of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum maintains metabolic activity / cell viability in the skin, increases metabolic activity / cell viability in the skin or slows down the decrease in metabolic activity and / or cell viability in the skin.

[0166] Embodiment 20. A bacterium for use according to embodiment 18, wherein the bacterium or a mixture thereof of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum maintains and stimulates the epidermal skin's natural and endogenous homeostatic cytokine production in keratinocytes.

[0167] Embodiment 21. Bacteria for use according to embodiment 20, wherein maintaining and stimulating the natural and endogenous homeostatic cytokine production of epidermal skin keratinocytes maintains metabolic activity / cell viability in the skin, increases metabolic activity / cell viability in the skin, or slows the decline in metabolic activity and / or cell viability in the skin.

[0168] Embodiment 22. A bacterium for use according to embodiment 18, wherein the bacterium is of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or a mixture thereof increases and improves the structural integrity and strength of the skin barrier.

[0169] Embodiment 23. The bacterium for use according to embodiment 22, wherein the increase and improvement of the structural integrity and strength of the skin barrier is achieved by the production of homeostatic cytokines in keratinocytes.

[0170] Embodiment 24. Bacteria for use according to embodiment 20, in which the maintenance and stimulation of the natural and endogenous homeostatic cytokine production of keratinocytes affects cells in the dermis, or fibroblasts, as well as their anti-aging activity and extracellular matrix production.

[0171] Embodiment 25. A bacterium for use according to any one of embodiments 18 to 24, wherein the bacterium of the species Ligilactobacillus salivarius is the Ligilactobacillus salivarius strain Ls-33 (Ls-33).

[0172] Embodiment 26. A bacterium for use according to any one of embodiments 18 to 24, wherein the bacterium of the species Lacticaseibacillus paracasei is the Lacticaseibacillus paracasei Lpc-37 (Lpc-37) strain.

[0173] Embodiment 27. A bacterium for use according to any one of embodiments 18 to 24, wherein the bacterium of the species Lacticaseibacillus rhamnosus is the Lacticaseibacillus rhamnosus HN001 (HN001) strain.

[0174] Embodiment 28. A bacterium for use according to any one of embodiments 18 to 24, wherein the bacterium of the species Lactiplantibacillus plantarum is the Lactiplantibacillus plantarum strain Lp-12407 (Lp-12407) and / or the Lactiplantibacillus plantarum strain Lp-12418 (Lp-12418).

[0175] Embodiment 29. A bacterium for use according to any one of embodiments 18 to 28, wherein the bacterium is of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or a mixture thereof is in live form.

[0176] Embodiment 30. A bacterium for use according to any one of embodiments 18 to 28, wherein the bacterium is of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or a mixture thereof, is in dissolved form.

[0177] Embodiment 31. A bacterium for use according to any one of embodiments 18 to 28, wherein the bacterium is of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or a mixture thereof, in postbiotic form.

[0178] Embodiment 32. The bacterium for use according to any one of embodiments 18 to 31, wherein the bacterium of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum or a mixture thereof is at least one component of a composition, a skin care composition, a dietary supplement, a nutraceutical, a food, or a pharma- ceutically acceptable composition.

[0179] Embodiment 33. A bacterium for use according to embodiment 32, wherein the composition, skin care composition or pharma- ceutically acceptable composition is for topical application.

[0180] Embodiment 34. The bacterium for use according to embodiment 32, wherein the composition, skin care composition, dietary supplement, nutraceutical, food or pharma- ceutically acceptable composition is for oral administration.

[0181] Embodiment 35. Non-therapeutic use of a composition comprising one or more bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, or a mixture thereof, for preventing, reducing, or treating skin aging in a subject.

[0182] Embodiment 36. A composition comprising one or more bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, or a mixture thereof, for use in preventing, reducing or treating skin aging in a subject.

[0183] Embodiment 37. A method for preventing, reducing or treating skin aging in a subject in need thereof, comprising administering to the subject an effective amount of a composition comprising one or more bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, or a mixture thereof. EXAMPLES

[0184] Materials and Methods Five DuPont Nutrition Biosciences ApS probiotic strains, Ligilactobacillus salivarius Ls-33, Lacticaseibacillus paracasei Lpc-37, Lacticaseibacillus rhamnosus HN001, Lactiplantibacillus plantarum Lp-12407 and Lactiplantibacillus plantarum Lp-12418, were tested for their effects on skin hydration, moisturization and anti-aging properties in vitro using normal human epidermal keratinocyte (NHEK) cells. Probiotic strains were tested as live, lysed, or postbiotic solutions with NHEK cells with or without hyperosmotic stress (NaCl).

[0185] The effect of the strains on NHEK cells was first examined by cell viability and confluency measurements. In addition to this, the effect of the strains on NHEK cells was studied by measuring the amount of selected molecules produced: IL-1α, IL-6 and IL-8.

[0186] NHEK cells Adult normal human epidermal keratinocytes (NHEK) (Gibco™) were maintained in EpiLife™ medium containing 60 μM calcium (Gibco™) supplemented with human keratinocyte growth supplement (HKGS) (Gibco™) in a 5% CO2 atmosphere at +37° C. For experiments, the earliest possible passage was utilized.

[0187] Probiotic Cell Cultures and Test Sample Preparation Ligilactobacillus salivarius strain Ls-33 (DSM 33831, DGCC9868) (commercially available from DuPont Nutrition Biosciences ApS), Lacticaseibacillus paracasei strain Lpc-37 (DSM 32661, DGCC4981) (commercially available from DuPont Nutrition Biosciences ApS), Lacticaseibacillus rhamnosus strain HN001 (DSM 22876, DGCC1460) (commercially available from DuPont Nutrition Biosciences ApS), Lactiplantibacillus plantarum strain Lp-12407 (DSM Lactiplantibacillus plantarum strain Lp-12418 (DSM 32654, DGCC12407) (available from DuPont Nutrition Biosciences ApS) and Lactiplantibacillus plantarum strain Lp-12418 (DSM 32655, DGCC12418) (available from DuPont Nutrition Biosciences ApS) were cultivated anaerobically at +37°C in MRS broth (Neogen). For studies with live and lysed bacteria as well as postbiotics, bacteria were grown until they reached the exponential growth phase. Bacterial cells and soluble metabolites were separated by centrifugation at 4000 rpm for 5 min at +4°C. The bacterial pellet (cells) was resuspended in either supplemented EpiLife® cell culture medium or differentiation medium (DM). Bacterial cell density was determined using an optical densitometer (BioPhotometer, Eppendorf) and flow cytometry (FACSCalibur, Becton Dickinson, San Jose, CA, USA).Bacterial cell lysates were prepared by shearing the cells with a Precellys 24 bead beater (Bertin Technologies, Saint Quentin-en-Yvelines Cedex, France) with a grinding kit VK01 (Bertin Technologies) at 6800 rpm for three cycles of 30 seconds. Cell disruption was confirmed by light microscopy. Bacterial cell lysates were sterile filtered with a 0.2 μm syringe unit (Sartorius) before they were applied to the keratinocytes. Live and lysed bacterial cells were administered as 100 bacterial cells per keratinocyte cell. Soluble metabolites were diluted to 10% (vol / vol) in either supplemented EpiLife® cell culture medium or differentiation medium (DM) and sterile filtered with a 0.2 μm syringe unit (Sartorius) before being applied to the cells.

[0188] Stress conditions Hyperosmotic stress for keratinocyte studies was induced by adding NaCl (JT Baker) to supplemented EpiLife® cell culture medium or differentiation medium (DM) to reach 150 mM molarity, which corresponds to an osmolality of approximately 570 mOsm / kg as measured by an osmometer (Ordior). Cells were stressed with the bacterial test solution, except for differentiated keratinocytes, where hyperosmotic stress was applied locally while the bacterial test solution was basolateral.

[0189] MTT and confluency assay The metabolic activity (viability) of cells after incubation with test samples was evaluated using the MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Briefly, to evaluate the metabolic activity of NHEK cells, 10 4Cells were seeded in wells of a 96-well plate (Nunc™ MicroWell™, Thermo Scientific) and after 24 hours, a 0,1 ml volume of test samples was applied topically. After 24 hours of incubation with NHEK cells, the test samples were removed and the cells were washed twice with phosphate-buffered saline (PBS) and treated with 0,5 mg / ml MTT (Sigma-Aldrich)-reagent solution (diluted in DMEM, Gibco) for 2 hours at +37°C and 5% CO2 atmosphere. The MTT solution was collected and replaced with 0,12 ml of dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and incubated in an orbital shaker for 5 minutes protected from light. A volume of 0,09 ml of supernatant was transferred to a 96-well plate and the absorbance of the samples was analyzed using an EnSight plate reader (Perkin Elmer, USA) measuring the absorbance at 570 nm (reducing background absorbance at 700 nm).

[0190] Confluency measurements were used to evaluate cell morphology-related information by determining the area covered by cells. Briefly, to evaluate cell confluency of NHEK cells, 10 4 Cells were seeded in wells of 96-well plates (Nunc™ MicroWell™, Thermo Scientific) and after 24 hours, cells were allowed to attach at +37°C, 5% CO2 atmosphere and a 0.1 ml volume of test samples was applied topically. After 24 hours of incubation with NHEK cells at +37°C, 5% CO2 atmosphere, test samples were removed and cells were washed twice with phosphate-buffered saline (PBS). Cell confluency was determined using bright-field imaging with an EnSight plate reader (Perkin Elmer, USA) and accompanying software (Kaleido, Perkin Elmer, USA).

[0191] ELISA assay A multiplex sandwich ELISA assay (Quanterix) was used to analyze the amount of human cytokines interleukins IL-1α, IL-6 and IL-8 produced from selected collected samples.

[0192] A transwell system forming two compartments was used with differentiated keratinocytes to determine the biomarkers produced with and without local stress conditions. To differentiate keratinocytes, cells were plated on ThinCert™ cell culture inserts (Greiner Bio-one) at 10 5 cells / cm 2 After 48 hours of incubation at +37°C in a 5% CO2 atmosphere, the medium was aspirated and replaced with differentiation medium (DM) consisting of EpiLife® medium supplemented with HKGS and containing 1.45 mM CaCl2, and incubated for 3 days in a 5% CO2 atmosphere.

[0193] On the third day after the start of differentiation, the medium was changed to fresh DM from both the basolateral and local sides and differentiation was checked by measuring the transepithelial electrical resistance (TEER) by a cellZscope device (nanoAnalytics GmbH). Afterwards, the cells were further incubated overnight at +37°C and 5% CO2 atmosphere before starting the experiment. Test samples were applied basolaterally in a volume of 1.5 ml and hyperosmotic stress was applied locally in a volume of 0.5 ml. After 24 h of incubation at +37°C and 5% CO2 atmosphere, samples for ELISA assays were collected from the basolateral side and stored frozen at -80°C until analysis.

[0194] All ELISA biomarkers were analyzed from collected cell culture samples according to the manufacturer's instructions.

[0195] statistical analysis For MTT and confluency assays and ELISA assays for biomarkers IL-1α, IL-6, and IL-8, statistical significance between treatments was determined using GraphPad Prism version 9.2.0 using one-way ANOVA and Dunnett's multiple comparison test, with a p value of 0.05 or less considered significant.

[0196] The resulting bar graphs show the mean ± standard deviation.

[0197] result metabolic activity The metabolic activity of cells represents the general health of the cells. The MTT method measures the cellular metabolic activity of live cells and the reduction potential of the cells, or the availability of reducing compounds to drive cellular energy. The MTT method is also utilized to measure cell viability. A higher absorbance value than the control indicates cell proliferation or higher metabolic activity, while a lower value suggests cell death or inhibition of proliferation or lower metabolic activity. A decrease in MTT activity in cells is considered an indicator of cellular redox activity. Senescent cells, or cells that are unable to divide, typically accumulate in aged and photoaged skin over time and may contribute to age-related skin changes and pathologies. Thinning of the epidermis associated with skin aging is caused in part by a decrease in the proliferation and regenerative capacity of basal keratinocytes, as well as a decrease in the number of epidermal stem cells. In addition, the dermal-epidermal junction (DEJ), which connects the epidermis to the underlying dermis, and the dermis itself become thinner. Senescent cells lose their functionality and also affect the surrounding cells by secreting a variety of molecules, including proinflammatory chemokines, cytokines and various proteases.

[0198] The hydration state of skin cells is important for their metabolic activity. Thus, one of the primary functions of the skin is to provide protection against dehydration and water loss. The skin of terrestrial animals, including humans, is exposed to environments with varying humidity, from 0 to 100% relative humidity. Relative humidity below 100% can cause significant dehydration or osmotic stress in the epidermis, which must respond to protect the organism from water loss. Aged skin is drier and has a stiffer epidermis than younger skin. Wrinkles are formed by folding of the epidermis together with bulk deformation of the dermis, and a dehydrated, stiffer epidermis resists folding stress more and therefore exhibits a less wavy surface, which means that dehydration produces wrinkles with greater amplitude and periodicity. With an adequate amount of water in the stratum corneum (SC), the skin maintains its intact barrier function, feels soft and supple, and appears smooth and healthy. Dryer skin exhibits more wrinkles and deeper grooves, with wider spacing.

[0199] NHEK Cell Metabolic Activity – NaCl Stress The metabolic activity of stressed NHEK cells was screened with the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay after incubating the cells with the test solution for 24 hours under hyperosmotic stress (induced by NaCl). The number of viable cells present is reflected in the ability of NAD(P)H-dependent cellular oxidoreductase to reduce the MTT reagent to insoluble formazan, which can be measured by absorbance analysis. Hyperosmotic stress disrupts the cellular osmotic balance. This was used to model dehydration.

[0200] During hyperosmotic stress induced by NaCl, live (32.30%, p=0.0027) and postbiotic forms (32.86%, p=0.0011) of Ls-33, live Lp-12407 bacteria (34.27%, p=0.0001), live Lpc-37 bacteria (47.75%, p<0.0001), postbiotic forms of Lp-12418 (32.41%, p=0.0023), and live (35.18%, p<0.0001) and postbiotic forms (30.33%, p=0.0401) of HN001 were able to increase metabolic activity (viability) of NHEK cells compared to NaCl-treated control cells (23.88%).

[0201] Hyperosmotic stress can cause cell metabolism to decrease, leading to cell aging.Probiotics Ls-33, Lp-12407, Lpc-37, Lp-12418 and HN001 strains can delay the decrease in metabolic activity and / or cell viability caused by hyperosmotic stress, which may refer to their ability to support cell proliferation and viability, and equalize the osmotic pressure difference of dehydrated skin, which may lead to signs of aging.

[0202] Confluency Visual inspection of cells and measurement of confluency determines the percent image area covered by cells or the area from a culture dish covered by cells. Increased confluency indicates either an increased number of cells, or that the cells are more spread out or better attached to the substratum, or that the volume of cells has increased. Spreading of epithelial sheets is a fundamental cellular process that must be coordinated with cell division and differentiation to restore tissue integrity. Dividing keratinocytes will participate in differentiation if cell confluency with increased cell density is high enough. Senescent cells present in aged skin are unable to divide, so increased confluency is beneficial.

[0203] In hyperosmotic stress, cell volume decreases and cell shrinkage occurs as a result of water outflow. In aged skin, blood circulation and expression of osmotic transporters in the dermis decrease, reducing cell volume recovery from osmotic stress. Hyperosmotic stress is also involved in proinflammatory signaling and thus accelerated aging. It causes the cessation of all major biosynthetic pathways, including DNA synthesis and repair, transcription, protein translation and degradation, and mitochondrial function. As a result, cell cycle progression and cell proliferation are halted. There is a concomitant increase in oxidative stress and activation of apoptotic pathways, which may result in a decrease in cell number.

[0204] NHEK cell confluency - no stress After incubating the cells with the test solutions for 24 hours, confluency, the area covered by the cells, was assessed by brightfield imaging and associated analysis software.

[0205] Live Lp-12407 bacteria (44.03%, p=0.0461) and postbiotic forms of Lpc-37 bacteria (44.65%, p=0.0171) had a statistically significant increase in NHEK cell confluency compared to the media control sample (38.45%) (Figure 2).

[0206] A slight increase in confluency may reflect increased cell mass and attachment to the well substrate. Under favorable conditions, cells will maintain and even increase proliferation with a concomitant balance in cell volume regulation.

[0207] NHEK Cell Confluency-NaCl Stress After 24 h of incubation in the presence of hyperosmotic stress, which perturbs the osmotic balance of the cells, the area covered by the cells, confluency, was assessed by brightfield imaging and accompanying analysis software. Confluency analysis reveals interesting information, especially under hyperosmotic conditions, as these conditions cause cells to shrink as they attempt to balance the osmotic difference.

[0208] During NaCl stress, several test compounds were able to restore cell confluency, among others, live (32.77%, p<0.0001) and postbiotic forms (22.83%, p=0.0351) Lp-12407, live Lpc-37 (31.00%, p<0.0001), live (30.89%, p<0.0001) and lysed (22.95%, p<0.0304) Lp-12418, and live HN001 (24.66%, p=0.0032) compared to NaCl control samples (15.84%) (Figure 3). Live Ls-33 (21.92%) also had some increasing effect on confluency compared to the hyperosmotic stress control (Figure 3).

[0209] All strains, Ls-33, Lp-12407, Lpc-37, Lp-12418 and HN001, were able to attenuate the cell shrinkage and cell detachment observed as a decrease in cell confluency in NaCl-stressed control samples, thus counteracting the deleterious effects of hyperosmotic conditions. This may point to the ability of strains Lp-12407, Lpc-37, Lp-12418 and HN001 to support skin cells during osmotic stress and dehydration that may cause skin aging.

[0210] NHEKS biomarkers - stress and no hyperosmolar stress Interleukin-1α (IL-1α) During exposure of keratinocytes to hyperosmotically stressed conditions, all strains and forms, live (p<0.0001), lytic (p<0.0166) and postbiotic (p<0.0001) forms of Ls-33; live (p<0.0001), lytic (p<0.0061) and postbiotic (p<0.0001) forms of Lp-12407; live (p<0.0001), lytic (p=0.0061) and postbiotic (p<0.0001) forms of Lpc-37, and live (p<0.0001), lytic (p=0.0 live (p<0.0001), soluble (p=0.0006) and postbiotic (p<0.0001) forms of Lp-12418; and live (p<0.0001), soluble (p=0.0024) and postbiotic (p<0.0001) forms of HN001 significantly increased IL-1α expression compared to controls (Figure 4).

[0211] Keratinocytes constitutively produce IL-1α, and their expression has a protective function through stimulation of keratinocyte proliferation and differentiation. IL-1α also stimulates the expression of other cytokines such as IL-6 and IL-8. Notably, IL-1α levels have been shown to be decreased in aged skin. IL-1α also has a role in stimulating and enhancing lipid synthesis in keratinocytes, which contributes to the formation of lipids that are part of the skin barrier. When the skin barrier was perturbed with tacrolimus in a mouse model, IL-1α increased barrier recovery and restored the permeability and antimicrobial barrier. In addition, it has been shown to upregulate the expression of genes related to cell adhesion, proliferation and junction formation, such as occludin and claudin-1. IL-1α stimulation in aged mouse epidermis improves barrier homeostasis. Thus, increasing IL-1α by probiotics increases survival and barrier repair and maintenance in the epidermis. Thus, increasing IL-1α would improve skin barrier function in a number of ways that benefit aged skin.

[0212] Interleukin-6 (IL-6) During exposure of unstressed keratinocytes, live (p<0.0001) and postbiotic (p<0.0001) forms of Ls-33; live (p=0.0005) and postbiotic (p<0.0001) forms of Lp-12407; and live (p<0.0001) and postbiotic (p<0.0001) forms of Lpc-37 were all able to significantly increase IL-6 production compared to controls.

[0213] During exposure of keratinocytes to hyperosmotic stress, live (p<0.0001) and postbiotic (p=0.0006) forms of Ls-33; all forms, live (p<0.0001), lysed (p<0.0001) and postbiotic (p<0.0001) forms of Lp-12407; live (p<0.0001) and postbiotic (p<0.0001) forms of Lpc-37; and live Lp-12418 (p=0.0003) and live HN001 (p=0.0015) strains significantly increased the expression of IL-6 compared to the control (Figure 5; Figure 6).

[0214] IL-6 can be induced by multiple stimuli, including UVB radiation, TLR stimulation, and various proinflammatory cytokines. IL-6 promotes keratinocyte proliferation, skin thickening, and skin barrier repair. Topical IL-6 application has been shown to improve skin barrier repair after mechanical injury. In particular, in aging skin, epithelial proliferation is desired to maintain a balance between basal and differentiated populations. Increased IL-6 indicates improved ability of NHEKs to proliferate and repair the skin barrier, which is beneficial for aging skin.

[0215] Interleukin-8 (IL-8) (also known as the chemokine CXCL8) During exposure of unstressed keratinocytes, live forms of strains Ls-33 (p<0.0001), Lp-12407 (p=0.0088), Lpc-37 (p<0.0001), and HN001 (p=0.0232) were all able to significantly increase IL-8 production compared to controls.

[0216] During exposure of keratinocytes to hyperosmotically stressed conditions, live (p=0.0003), soluble (p<0.0001) and postbiotic (p<0.0001) forms of Ls-33; live (p<0.0001), soluble (p<0.0001) and postbiotic (p<0.0001) forms of Lp-12407; live (p<0.0001), soluble (p<0.0001) and postbiotic (p<0.0001) forms of Lpc-37; live (p<0.0239) and postbiotic (p<0.0001) forms of Lp-12418; and live (p=0.0002) and postbiotic (p<0.0001) forms of HN001 significantly increased IL-8 production compared to controls (Figure 7).

[0217] Chemokines, including IL-8, regulate normal keratinocyte proliferation and differentiation. IL-8 is expressed during injury and can be induced by proinflammatory cytokines such as IL-1 or TNF-α. It stimulates keratinocyte migration and proliferation. In particular, in aging skin, epithelial proliferation is desired to maintain a balance between basal and differentiated populations. Thus, an increase in IL-8 indicates an improvement in the ability of NHEKs to proliferate and repair the skin barrier, which is beneficial for aging skin.

[0218] All publications mentioned in the above specification are incorporated herein by reference. Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the art of biochemistry and biotechnology or related fields are intended to be within the scope of the following claims.

Claims

1. 1. Non-therapeutic use of bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, or Lactiplantibacillus plantarum, or mixtures thereof, for preventing, reducing or treating skin aging in a subject.

2. 2. The non-therapeutic use of claim 1, wherein the bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or mixtures thereof maintain metabolic activity / cell viability in the skin, increase metabolic activity / cell viability in the skin or slow the decline in metabolic activity and / or cell viability in the skin.

3. 2. The non-therapeutic use according to claim 1, wherein the bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or mixtures thereof maintain and stimulate the natural and endogenous homeostatic cytokine production of epidermal skin in keratinocytes.

4. 4. The non-therapeutic use of claim 3, wherein maintaining and stimulating the natural and endogenous homeostatic cytokine production of the epidermal skin of the keratinocytes maintains metabolic activity / cell viability in the skin, increases metabolic activity / cell viability in the skin, or slows the decline in metabolic activity and / or cell viability in the skin.

5. 5. The non-therapeutic use according to any one of claims 1 to 4, wherein the bacterium of the species Ligilactobacillus salivarius is the Ligilactobacillus salivarius strain Ls-33 (Ls-33).

6. 5. The non-therapeutic use according to any one of claims 1 to 4, wherein the bacterium of the species Lacticaseibacillus paracasei is Lacticaseibacillus paracasei strain Lpc-37 (Lpc-37).

7. 5. The non-therapeutic use according to any one of claims 1 to 4, wherein the bacterium of the species Lacticaseibacillus rhamnosus is the Lacticaseibacillus rhamnosus HN001 (HN001) strain.

8. 5. The non-therapeutic use according to any one of claims 1 to 4, wherein the bacterium of the species Lactiplantibacillus plantarum is Lactiplantibacillus plantarum strain Lp-12407 (Lp-12407) and / or Lactiplantibacillus plantarum strain Lp-12418 (Lp-12418).

9. 9. The non-therapeutic use according to any one of claims 1 to 8, wherein the bacteria of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or mixtures thereof is an ingredient of at least one of a composition, a skin care composition, a dietary supplement, a nutraceutical, a food or a pharma-ceutically acceptable composition.

10. 1. A bacterium of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or a mixture thereof for use in preventing, reducing or treating skin ageing in a subject.

11. 11. The bacterium for use according to claim 10, wherein the bacterium of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or a mixture thereof maintains metabolic activity / cell viability in the skin, increases metabolic activity / cell viability in the skin or slows the decrease in metabolic activity and / or cell viability in the skin.

12. 11. The bacterium for use according to claim 10, wherein said bacterium of the species Ligilactobacillus salivarius, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus or Lactiplantibacillus plantarum or mixtures thereof maintains and stimulates the natural and endogenous homeostatic cytokine production of epidermal skin in keratinocytes.

13. The bacterium for use according to claim 12, wherein maintaining and stimulating the natural and endogenous homeostatic cytokine production of the epidermal skin of the keratinocytes maintains metabolic activity / cell viability in the skin, increases metabolic activity / cell viability in the skin, or delays the decline in metabolic activity and / or cell viability in the skin.

14. The bacterium for use according to any one of claims 10 to 13, wherein the bacterium of the species Ligilactobacillus salivarius is the Ligilactobacillus salivarius Ls-33 (Ls-33) strain.

15. The bacterium for use according to any one of claims 10 to 13, wherein the bacterium of the species Lacticaseibacillus paracasei is Lacticaseibacillus paracasei strain Lpc-37 (Lpc-37).

16. 14. The bacterium for use according to any one of claims 10 to 13, wherein the bacterium of the species Lacticaseibacillus rhamnosus is the Lacticaseibacillus rhamnosus HN001 (HN001) strain.

17. The bacterium for use according to any one of claims 10 to 13, wherein the bacterium of the species Lactiplantibacillus plantarum is Lactiplantibacillus plantarum strain Lp-12407 (Lp-12407) and / or Lactiplantibacillus plantarum strain Lp-12418 (Lp-12418).

Citation Information

Patent Citations

  • Lactic acid bacteria with immune-enhancing effects

    JP2001513990A

  • COMPOSITION COMPRISING LACTOBACILLUS PLANTARUM FOR PREVENTING AND / OR TREATING MENTAL DISORDERS - Patent application

    JP2021506302A

  • Ferment collagen for preventing skin aging and improving skin wrinkle and preparing method same

    KR1020170143478A

  • Anti-aging cosmetic compositions containing lactic acid bacteria, fermented lactic acid bacteria and natural extracts, and method for manufacturing the same

    KR102235470B1

  • Probiotic bacteria for the topical treatment of skin disorders

    US20160008412A1

Cited By

  • Lacticaseibacillus rhamnosus ICL-46 strain derived from oat and its use for Anti-inflammation, Anti-allergy, skin immunity enhancement, atopic dermatitis improvement, skin soothing and skin microorganism regulation

    JP2025114485A